• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Cost-Effectiveness of Dabigatran (150 mg Twice Daily) and Warfarin in Patients ≥65 Years With Nonvalvular Atrial Fibrillation
Dabigatran has been shown to be superior to warfarin for stroke prevention in nonvalvular atrial fibrillation (NVAF) but with higher out-of-pocket costs for patients. Although dabigatran has been shown to be cost effective from a societal perspective, cost implications for individual patients and insurers are not well described. We aimed to assess cost perspectives of each payer (Medicare and patient) in relation to administration, monitoring, and adverse outcomes for dabigatran and warfarin in patients with and without prescription drug coverage.
Source: The American Journal of Cardiology - October 16, 2015 Category: Cardiology Authors: Brian M. Salata, David W. Hutton, Deborah A. Levine, James B. Froehlich, Geoffrey D. Barnes Tags: Arrhythmias and Conduction Disturbances Source Type: research

Cost-Effectiveness of Dabigatran (150 mg Twice Daily) and Warfarin in Patients ≥ 65 Years with Non-Valvular Atrial Fibrillation
Dabigatran has been shown to be superior to warfarin for stroke prevention in non-valvular atrial fibrillation (NVAF) but with higher out-of-pocket costs for patients. Although dabigatran has been shown to be cost-effective from a societal perspective, cost implications for individual patients and insurers are not well-described. We aimed to assess cost perspectives of each payer (Medicare and patient) in relation to administration, monitoring and adverse outcomes for dabigatran and warfarin in patients with and without prescription drug coverage.
Source: The American Journal of Cardiology - October 16, 2015 Category: Cardiology Authors: Brian M. Salata, David W. Hutton, Deborah A. Levine, James B. Froehlich, Geoffrey D. Barnes Source Type: research